MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services. The company also provides maternal-fetal care, including inpatient and office-based clinical care to expectant mothers and their unborn babies through maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians consisting of maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, its pediatric cardiology care services comprise inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through pediatric cardiologist subspecialists and other related clinical professionals. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, and pediatric surgeons, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. Additionally, it provides radiology and teleradiology services. As of December 31, 2017, the company's network consisted of approximately 4,075 affiliated physicians. MEDNAX, Inc. was founded in 1979 and is based in Sunrise, Florida.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Hospitals
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNYSE:MD
Previous SymbolNYSE:PDX
CUSIP58502B10
Phone954-384-0175
Debt
Debt-to-Equity Ratio0.67
Current Ratio1.43
Quick Ratio1.43
Price-To-Earnings
Trailing P/E Ratio11.26
Forward P/E Ratio11.00
P/E Growth1.05
Sales & Book Value
Annual Sales$3.46 billion
Price / Sales1.02
Cash Flow$4.2789 per share
Price / Cash9.18
Book Value$33.72 per share
Price / Book1.16
Profitability
EPS (Most Recent Fiscal Year)$3.15
Net Income$320.37 million
Net Margins9.50%
Return on Equity10.45%
Return on Assets5.53%
Miscellaneous
Employees7,675
Outstanding Shares89,420,000
Market Cap$3.51 billion
OptionableOptionable
MEDNAX (NYSE:MD) Frequently Asked Questions
What is MEDNAX's stock symbol?
MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."
How were MEDNAX's earnings last quarter?
MEDNAX Inc (NYSE:MD) released its earnings results on Thursday, November, 1st. The company reported $0.94 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.97 by $0.03. The business had revenue of $896.60 million for the quarter, compared to analysts' expectations of $908.15 million. MEDNAX had a net margin of 9.50% and a return on equity of 10.45%. MEDNAX's revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.87 earnings per share. View MEDNAX's Earnings History.
When is MEDNAX's next earnings date?
What guidance has MEDNAX issued on next quarter's earnings?
MEDNAX issued an update on its fourth quarter earnings guidance on Thursday, November, 1st. The company provided EPS guidance of $0.87-0.95 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.01. MEDNAX also updated its Q4 2018 guidance to $0.87-0.95 EPS.
What price target have analysts set for MD?
14 equities research analysts have issued 12 month target prices for MEDNAX's stock. Their forecasts range from $37.00 to $62.00. On average, they expect MEDNAX's share price to reach $50.5714 in the next twelve months. This suggests a possible upside of 28.7% from the stock's current price. View Analyst Price Targets for MEDNAX.
What is the consensus analysts' recommendation for MEDNAX?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last year. There are currently 1 sell rating, 9 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MEDNAX.
Has MEDNAX been receiving favorable news coverage?
News coverage about MD stock has been trending somewhat negative recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. MEDNAX earned a news impact score of -1.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the company's share price in the near term.
Who are some of MEDNAX's key competitors?
Some companies that are related to MEDNAX include Encompass Health (EHC), Select Medical (SEM), Magellan Health (MGLN), Animalcare Group (ANCR), Capitol Health (CAJ), Healthscope (HSO), Medical Facilities (DR), Primary Health Care (PRY), Ramsay Health Care Limited Fully Paid Ord. Shrs (RHC), Spine Injury Solutions (SPIN), SunLink Health Systems (SSY) and THC Biomed Intl (THC).
Who are MEDNAX's key executives?
MEDNAX's management team includes the folowing people:
- Dr. Roger J. Medel, Co-Founder, CEO & Director (Age 71)
- Mr. Joseph M. Calabro, Pres & COO (Age 57)
- Ms. Vivian Lopez-Blanco, CFO & Treasurer (Age 60)
- Mr. Dominic J. Andreano, Sr. VP, Gen. Counsel & Sec. (Age 49)
- Mr. David A. Clark, Pres of Mednax National Medical Group Division (Age 51)
Who are MEDNAX's major shareholders?
MEDNAX's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.34%), Pzena Investment Management LLC (3.64%), Credit Suisse AG (2.74%), Dimensional Fund Advisors LP (2.50%), FMR LLC (2.14%) and Bank of New York Mellon Corp (1.97%). Company insiders that own MEDNAX stock include Cesar L Alvarez, David A Clark, Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Manuel Kadre, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Paul G Gabos, Robert Irwin Valliant and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX.
Which major investors are selling MEDNAX stock?
MD stock was sold by a variety of institutional investors in the last quarter, including Thompson Siegel & Walmsley LLC, Credit Suisse AG, Wells Fargo & Company MN, Toronto Dominion Bank, JPMorgan Chase & Co., JPMorgan Chase & Co., Wedge Capital Management L L P NC and Allianz Asset Management GmbH. Company insiders that have sold MEDNAX company stock in the last year include David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro and Vivian Lopez-Blanco. View Insider Buying and Selling for MEDNAX.
Which major investors are buying MEDNAX stock?
MD stock was bought by a variety of institutional investors in the last quarter, including Pzena Investment Management LLC, Bank of New York Mellon Corp, Point72 Asset Management L.P., Renaissance Technologies LLC, Hsbc Holdings PLC, Bank of Montreal Can, BlackRock Inc. and Ardevora Asset Management LLP. Company insiders that have bought MEDNAX stock in the last two years include Manuel Kadre and Md Pascal J Goldschmidt. View Insider Buying and Selling for MEDNAX.
How do I buy shares of MEDNAX?
Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MEDNAX's stock price today?
One share of MD stock can currently be purchased for approximately $39.28.
How big of a company is MEDNAX?
MEDNAX has a market capitalization of $3.51 billion and generates $3.46 billion in revenue each year. The company earns $320.37 million in net income (profit) each year or $3.15 on an earnings per share basis. MEDNAX employs 7,675 workers across the globe.
What is MEDNAX's official website?
How can I contact MEDNAX?
MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]
MarketBeat Community Rating for MEDNAX (NYSE MD)
MarketBeat's community ratings are surveys of what our community members think about MEDNAX and other stocks. Vote "Outperform" if you believe MD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MD will underperform the S&P 500 over the long term. You may vote once every thirty days.
